American Well Corporation (AMWL) Earnings Call Transcript
August 4, 2026
Earnings Call Speaker Segments
Good evening, everyone, and thanks for being here on our second-quarter earnings call. As we shared not long ago, an important milestone has been reached. A notice of intent to award a sole source contract straight to Amwell came from the Defense Health Agency; the DHA's decision has us thrilled, since it points to a chance to deepen and broaden our relationship over many years ahead. In choosing this path, the government is deliberately building its core platform around the partners it relies upon. The DHA's move fits with the policy direction it has set to secure long-term gains in cost efficiency. Operations keep right on going now that we've moved to direct contracting, and care that crosses agency lines remains steady with no disruption. We really value the confidence they place in us. MHS GENESIS, which acts as the cornerstone of the single federal health IT ecosystem, already contains our platform. In combat theaters, deployed units have been connected through Amwell's platform to hospitals in their home country. It's a point of pride to serve the 9.6 million service members, families, and retirees within the Military Health System, and we're committed to delivering for them daily. Looking at the bigger picture, our approach is simple. Everything revolves around the unified Amwell platform. From us, clients get the top-tier infrastructure for care powered by technology. We're talking about a single platform rather than a bunch of separate ones. Government agencies, payers, and health systems rely on it so that patients get an experience that's simple and streamlined. Members can tap into an expanding set of clinical programs, and as they do, the improvements they see in both clinical and financial results are measurable. This focus shows up in how our revenue is mixed. These days, subscription revenue makes up over half of what we bring in overall; that's recurring, stable revenue of high quality. A business that's healthier and more predictable rests on that foundation. Throughout all of 2026, we're working to deliver an improved user experience. We've also significantly strengthened our ability to engage members and get them activated into care. The platform gets clinical partners up and running fast, converts what they collect into actionable intelligence, and operates at the level of dependability and regulatory adherence that our customers count on. Put simply, we're simpler to bring on board, simpler to develop against, and simpler to place faith in. Let me drill into the value we deliver, since that sits at the core of our narrative. Payers face genuine strain. What they charge in premiums isn't matching the climb in care expenses. Technology, along with AI-driven care, ranks among the strongest instruments available to them for containing cost and lifting outcomes. Appetite exists, yet translating it into action has proven difficult. A lot of payers find themselves stuck with vendor sprawl—dozens of individual point solutions that cost a fortune to link up and can't be compared to each other in any meaningful way. Fed up with all that fragmentation, payers and employers are looking more and more for a smaller number of deeper partnerships. They want one partner capable of addressing many needs via a single relationship. Amwell exists to solve exactly this problem; what we provide is one unified platform for customers, so the job of stitching dozens of vendors together no longer falls on them. Behind their own brand and their own front door, they place one Amwell gateway. Upon signing up, a person gets one simple, straightforward place to reach whatever programs they need, and the member relationship remains with our customer. Through that entry point, customers are able to blend and switch among offerings — ours, one from a partner, or one of their own. They can replace them rapidly with no disruption to how members experience things. Since each program operates on one shared platform, we unify all of the data; customers can now, for the very first time, plainly observe what's performing, demonstrate both clinical and financial outcomes, and make adjustments live. What we offer isn't an AI feature for sale; we are the trusted setting in which care powered by AI operates. DarioHealth's recent news that it will add a new program to the Amwell healthcare marketplace in Arizona gave us a plain example of this. There's another shift in the market that raises the stakes further. Buyers are paying more and more attention to real usage. How engaged people are is no longer a soft measure. It drives the finances. Getting members into the proper care, making their health better, and steering clear of costly downstream expenses is where value comes from; that is precisely what our platform was designed to accomplish. A single front door makes services simple to locate and utilize. Our analytics and data fuel personalized, targeted outreach. Partnering tightly with employers and health plans, we convert members into active users, and we can demonstrate it; during this quarter, a randomized trial involving our SilverCloud behavioral health program appeared in "Nature Human Behaviour." The National Institute of Mental Health paid for it, and investigators from Washington University, Penn State, and UCLA led it; over two years it tracked more than 6,200 students, making it one of the biggest studies of its type. The findings were unambiguous. Students who were offered SilverCloud participate at over twice the rate seen with traditional care; across two years they showed lower rates of mental health disorders, and the study indicated roughly $1.2 million in costs avoided within the study group by itself. Payers are looking for exactly this: better engagement, stronger results, lower costs, and verification from an independent source. In the market, our momentum continues to grow. Our pipeline continues to get bigger. Renewals are holding up well. With new prospects across both the commercial and government sectors, we're having promising discussions. We also moved closer this quarter to a target we've clearly stated: generating positive cash flow from operations by the fourth quarter of 2026. That won't be a one-time result. It establishes a durable foundation for sound growth in 2027 and afterward. We have taken an intentional path to reach this point. Across 2025, we reduced our losses by roughly $100 million. In the Q2, our adjusted EBITDA loss of roughly $1 million is the nearest we've come to breakeven since becoming a public company and leaves us more confident about hitting our target of positive adjusted EBITDA in the Q4. We managed this while keeping over $195 million in cash and holding no debt. We possess the runway to execute, and a team dedicated to doing so with discipline. We're accomplishing all of this with a linear cost structure. What enables that is our disciplined operations and strategy centered on a focused platform, which includes weaving AI through all our workflows. Beneath everything lies a culture driven by purpose—something far tougher to copy—that draws in and inspires outstanding talent. Allow me to wrap up by explaining why this is so important at this moment. With care powered by AI speeding up, the burden placed on payers just keeps increasing. Given those conditions, having one dependable infrastructure layer turns into a necessity. Amwell is exactly that. No longer a telehealth vendor, we have finished becoming the infrastructure supporting care programs driven by AI. What we now have is a mature platform, streamlined operations, solid finances, and unbiased evidence that our offerings perform as promised. Our confidence is high regarding reaching adjusted EBITDA breakeven during this year's Q4. The expansion coming afterward has us enthusiastic. Having said that, I will hand things over to Mark so he can guide you through the operational and financial metrics. Mark?
Thank you, Ido. Hello, everyone, and good afternoon. During this call, I'll begin by sharing several Q2 highlights, then take you through the details of our financial performance. I'll wrap up with an update regarding our outlook for both Q3 and the full year 2026. During Q2, our revenue came in as we had anticipated, which speaks to ongoing subscription stability along with a beneficial mix shift inside our visit portfolio. Adjusted EBITDA came in a bit better than we had expected, mainly because of ongoing cost discipline throughout the company. These outcomes extend the momentum we talked about three months ago. They also strengthen our confidence about achieving cash flow breakeven during Q4 of this year. Q2 total revenue reached $52 million, a decline of roughly 26.6% versus the same period last year. Subscription revenue came to $25.7 million, roughly 36.5% lower than a year ago, but roughly 3.2% higher than Q1 on a sequential basis. The year-over-year drop still mirrors the churn we disclosed previously, plus a one-time subscription revenue benefit recorded in last year's Q2 tied to rolling out our platform across the DHA. On an encouraging note, the sequential gain mirrors the stability we keep observing within our core payer and government subscription base. Amwell Medical Group, or AMG, visit revenue reached $24.4 million, roughly 7.4% higher than a year ago. AMG paid visits came to roughly 315,000 visits, unchanged versus a year ago, while revenue per visit stood at roughly $77 per visit, an increase of roughly $4, or 6%, per visit versus last year. This mirrors the ongoing shift in our visit mix toward higher acuity, higher value clinical programs along with virtual primary care. Virtual primary care visits rose roughly 30% versus a year ago, extending their robust growth trajectory. Total platform visits came to roughly 835,000 visits, roughly 28.4% below last year, yet in line with the portfolio changes we've discussed before. Gross profit reached $27.6 million, with a gross margin of 53%, roughly 310 basis points lower than a year ago, when it was 56.1% in Q2 of 2025. Sequentially, it rose roughly 200 basis points. As we've pointed out, our current revenue mix produces a margin profile largely in line with recent quarters, and we still anticipate that our revenue mix will move toward higher margin SaaS offerings over time. Total operating expenses, depreciation and amortization included, came to $37.1 million, roughly 38% lower than a year ago and roughly 18% lower sequentially. Measured as a percentage of revenue, operating expenses improved to 71.3%, versus 84.8% in Q2 of last year, which mirrors the ongoing benefit from our transformation actions and continuous cost discipline throughout Amwell. Adjusted EBITDA for Q2 was a loss of $1.15 million, versus a loss of $4.7 million in Q2 of 2025. Operating loss was $9.6 million, versus $20.4 million in Q2 of 2025, an improvement of roughly 53% versus a year ago. Now to the balance sheet. We closed Q2 with $196 million in cash and marketable securities along with zero debt; moving on to guidance. For Q3 of 2026, we anticipate revenue between $46 million- $48 million and an Adjusted EBITDA loss between — $5 million and — $3 million. This guidance takes into account the usual seasonal patterns we see in visit volumes as we progress through the rest of the summer, plus the ongoing steadiness in our subscriber base. The sequential decline in Adjusted EBITDA between 2Q and 3Q comes from costs tied to wrapping up certain internal projects, which we anticipate finishing before this year ends. Looking at the full year, we're tightening our revenue range while lifting our Adjusted EBITDA range in light of how we've performed so far this year. Our updated expectation for full year 2026 revenue is now between $200 million and $205 million, which means we've raised the bottom end of the $195 million to $205 million range we gave previously. On full year Adjusted EBITDA, we're now guiding to a loss between — $9 million and — $7 million, a significant improvement over the earlier range of a loss of $16 million to $12 million. We still anticipate full year AMG visits landing near the top of the 1.32 million to 1.37 million visit range we shared before. To sum up, Q2 represented another move forward in our effort to right-size the company and push toward profitability. Sustained subscription stability, a favorable mix of visits, and a leaner cost structure give us confidence that we're still on track to hit our cash flow breakeven goal in the Q4. I'd like to thank everyone on the Amwell team for their ongoing hard work and commitment. These results are a testament to their dedication and tremendous efforts. With that, I'll hand it back to Ido.
Thank you, Mark. Before we begin taking your questions, allow me to share the points that count the most. To start, the DHA's plan to grant a sole source contract straight to Amwell stands as a strong sign of trust. It strengthens the alliance that sits at the center of the Military Health System and confirms our role as core infrastructure for the unified federal health IT ecosystem, a chance we anticipate building upon for many years. Next, the caliber of our business continues to rise. Subscription revenue now makes up over half of total revenue and rose sequentially during this quarter. That recurring, steady base is what renders Amwell more predictable and more valuable as time passes. Third, our strategy is landing well in the market. Payers prefer fewer, deeper partnerships, and our single unified platform was designed exactly for that. We don't merely assert results anymore, we demonstrate them. The independently conducted study, published in Nature Human Behaviour, revealed engagement that more than doubled, improved outcomes, and meaningful avoided costs. That is the proof payers seek, and it's fueling a growing pipeline along with strong renewals. Fourth, our discipline is paying off. An adjusted EBITDA loss of roughly $1 million, the nearest we have ever come to breakeven as a public company. Raised full year adjusted EBITDA guidance. Almost $200 million in cash and no debt. We remain firmly on track for positive adjusted EBITDA and positive operating cash flow in the Q4, and that milestone isn't the finish line; it is the bedrock for healthy, durable growth in 2027 and beyond. Amwell has finished its transformation; we possess the platform, the proof, the partnerships, and the financial strength to lead as AI-powered care speeds up. I want to thank the Amwell team for their outstanding work and our shareholders for their continued trust. With that, we're now glad to open the call for your questions. Operator, please go ahead.
Hi there, Matt Shea here, filling in for Ryan. Appreciate you fielding this. I want to begin with the DHA contract. I'm not quite certain how to frame this best, but really the goal is to help us connect the gap between what the DHA intends. It sounds like your team holds the leading position, moving from that intent toward real execution — so what remains at this point? How would that schedule look from now until the contract is finalized? I believe during the previous quarter you mentioned there was a chance to bring in extra programs that hadn't been part of the earlier implementation, particularly the mental health program. What's the status of that possibility right now, and how do you expect that timeline to unfold too?
Hello, this is Mark. Here's the situation regarding the negotiations currently underway. Back in June, the DHA issued a release requesting a direct sole source contract with Amwell along with four other vendors. Right now, every one of us is in talks with the DHA. They set a deadline of July 30th of this year, aiming to have a number of those contracts up and running. As tends to happen in situations like this, each party needed extra information and more time. Their absolute final date is July of next year, and based on our recent discussions, including just this past week, their plan was to take another couple of months for negotiating; those talks are happening right now. They've indicated a desire to make the switch as quickly as they can; we're collaborating very closely with our trusted partners at Leidos as well as the DHA to ensure this transition goes as smoothly as it possibly can.
All right, that's useful.
Yes. Regarding the latter portion of what you asked, I believe it most probably pertains to SilverCloud, our behavioral health product, which we actually kept live and operational in that setting for a handful of months during the prior year; following the difficulties involving DOGE along with various other factors that undermined our capacity to maintain that standard of service, a decision was reached that we would bring that product back, alongside securing our direct sole-sourced contract. Discussions on that matter are likewise in progress, and the earliest point at which we anticipate being able to activate those services would fall in 2027.
Alright, that's really useful, Mark. Thanks for that. Perhaps shifting over to the payer side. If I recall correctly, during the prior quarter you mentioned bringing Amwell back in front of a number of health plans, and part of that charge involves re-entering the marketplace since you feel Amwell's relevance had been misplaced. Given the Elements and DHA rollouts, that credibility is returning. So first off, how crucial is the DHA renewal in bolstering that credibility story? And second, which is really the core of what I'm asking, it sounds like there are some marketing pushes supporting this reintroduction to health plans, so it would help to possibly learn how you're framing Amwell to health plans during this selling season, what marketing spend you have going, or what's landing so far. Do those efforts suffice to convert into January 1, 2027 wins, or is this instead a developing opportunity that may not gain traction until, let's say, the following selling season? Sorry, I realize that's a lot, I just consider it a key subject.
I'll have Ido handle that opening portion.
Okay, sorry.
Okay?
Yeah. Can you hear me now? Can you hear me?
Yes.
Yes.
Okay.
Yeah.
Matt, that's a terrific question — I appreciate it. Without a doubt, the DHA partnership, something we take a lot of pride in, represents a significant milestone and a strong piece of evidence. They are definitely not the only such example — others exist that have been made public, and more are on the way. It absolutely builds momentum. The DHA's infrastructure is widely shared throughout the whole government infrastructure landscape, and the fact that we can serve such a big audience at that scale with the kind of outcome that's been shown — underscored so meaningfully by their choice to go sole source, which typically signals, and they indicated as much, a very long-term commitment of at least three to five years — tells you how things are trending, and the broader government market has absolutely taken notice. In a lot of ways, the challenges government players face resemble those of commercial payers. Basically, stepping back for a moment, the core problem today is that care costs keep climbing sky-high. Getting members to adopt technology-enabled care is highly inefficient and ineffective, and once they do participate, grasping and demonstrating the results gets more and more complex when there are so many vendors — there's vendor fatigue, assembling that data is incredibly difficult, and so forth — and that is precisely our opening. The reason this market is so receptive is pretty straightforward. First, nearly every customer and prospective customer we have suffers from vendor sprawl and vendor fatigue. They bring on more and more staff to oversee more and more relationships that frequently don't deliver. The pressure — driven by escalating care costs and the inability to raise premiums to match, leaving margins strained — pushes them hard toward improving care efficiency, and that is fundamentally what we do. Technology-enabled care delivers a wonderful member experience, and it's also a means of drawing in and keeping members and giving clients reassurance. The fact that the platform sits within their infrastructure and under the trusted brand matters greatly. In essence, during this period of distress they're very willing to discuss consolidation and simplification of something that could be a crucial lifeline for them, in pursuit of better financial and clinical results. That's precisely who we are. Fewer integrations beneath a recognized brand — their brand — without surrendering the patient-member relationship to anybody. We've demonstrated at the DHA and in other places that we're quite good at bringing people to their digital door, to their infrastructure. We don't just sit there — we activate members, applying technology and clinical metrics. AMG's infrastructure, for instance, is a highly important piece of technology-enabled care, one component of what we offer that enables lasting, recurring bonds between physicians and patients — not a dead end, but instead an orchestration layer for a widening range of AI-powered care; it functions extremely well as a gateway and an enabler. In discussing this care, what we provide are our very own in-house offerings — there are a great many of them: urgent care, primary care, behavioral health. Mark discussed how that area has grown, along with nutrition, psychiatry, and the like, plus an expanding lineup of partners — Sword, Hello Heart, Vida, Dario, DermatologistOnCall, just to give several examples. Even more crucially, the demand placed on us is demonstrating results, so we've constructed a data infrastructure that lets us assemble the outcomes and genuinely grasp which things succeed and which don't. Whenever a program fails, or fails to perform adequately, we can swap to different offerings with great ease. In a period when fresh programs emerge daily, our clients can serve their own customers in a highly flexible manner. How this whole Amwell offering is embraced differs greatly from how traditional telehealth, for instance, was embraced — and it's delivering. I won't list every name, since the majority of those listening are familiar with our clients. They are extremely large. You brought up marketing toward those payers and government entities; our team is highly experienced. The customers we serve are substantial. Engaging those platforms doesn't require us to field an army. Nobody purchases those platforms according to the season. You wouldn't buy database infrastructure during the summer. What we offer our customers is a strategic answer that is indispensable now more than it has ever been — and it's delivering. Our twenty years of expertise are evident. They recognize they can rely on us; they recognize they can rely on us to lift a great deal of weight off their shoulders and to manage this menagerie, this ever-shifting assortment of clinical programs — with no new integrations, no numerous contracts, no stitching together separate data pieces, and while safeguarding against downside risks in domains such as cybersecurity, privacy, and compliance, all of which matter enormously as well. I realize that was quite a lot. A fairly lengthy response to a brief question. These factors explain why you're seeing the results you're seeing, and they explain why I stated that I'm deeply optimistic regarding our growth in 2027 and past that point. We're witnessing it at this very moment. Receptivity is strong. The pipeline keeps expanding. There's considerable activity on the sales front. Even more crucially, we observe the effect on customers we already have. Consider a few of them — we're discussing organizations with tens of millions of prospective members. Today, across the board, just a small number of members actually sign up — fewer than half in certain instances. Only 4% or 5%, and I'm optimistic, truly participate and produce outcomes. We're altering that, and the financial effect and worth to payers and the people they serve is massive. I doubt we've ever felt more optimistic than we do now. I doubt we've ever been more focused than we are. Being out there right now in the market with the customers we already have and the ones just coming on board is genuinely a joy, and you can see that sparkle in their eyes when we take care of a problem that sits at the top of their list.
Good to hear that. Thanks for the update, Ido. Appreciate it.
Hello. Could you discuss how EBITDA moves from a loss in Q2 to breakeven in Q4, and roughly what the plan is to reach that point? Also, perhaps you could give us an update on the cost restructuring work you've been doing? Thanks a lot.
Yes, absolutely. At the start of the year, we said there would be a set of costs that would run their course, or would get us to a position where several quarters of effort would carry us toward breakeven by year-end. Some project-related work began late last year. That carried into the early part of this year; it's now winding down during Q3. Even though one quarter will show a modest level of losses, we have strong visibility and a fair amount of confidence regarding what those costs will look like across the coming months, which is why we feel very sure that cash flow breakeven and adjusted EBITDA breakeven will be reached in Q4. On a conservative basis, we've provided a range for full-year EBITDA. Clearly, our internal objective is to exceed it. We've managed to do so across the past several quarters, delivering stronger bottom line and top line figures, and I think we've been quite conservative on the top line too. Assuming things stay as they are with our current clients, we haven't factored in any additional revenues, aside from a slight seasonal lift in Q4 for visit volume.
All right. When we look ahead to 2027, could you give us a bit more detail on things like backlog figures? Do you actually monitor that kind of metric? Bookings, or anything regarding the retention rates you'd expect in 2027? Essentially, at a broad level, and without offering guidance, will your revenue increase compared with the prior year in 2027? Thanks.
Yes. Clearly, we'll provide far greater visibility regarding what we expect for 2027, possibly sooner than when this year wraps up. Should the potential customers we're presently in talks with on the government side actually materialize, and should contracts get signed, that would hand us a substantial amount of visibility regarding revenue growth in 2027. From an internal standpoint, once more, we'd want to see this company get back to double-digit growth. In our view, that is quite achievable once the contracts now being negotiated with those clients who make up the bulk of our pipeline are finalized.
Just one more from me, if that's okay. Regarding that DHA contract and the plan to give Amwell a sole source award — first, was that a renewal? Is there any additional revenue connected to it? Second, I believe you mentioned that four other vendors were part of that. Could you clarify, because when I hear "sole source," it sounds like Amwell is the only company that got an award, but I heard you say four other vendors might have received something too. Do you know what revenue you'll see from that deal, or is everything still being sorted out? Thanks.
Yeah. The release I'm talking about concerns the new model — DHA said they will contract straight with proprietary solution providers for their core system capabilities instead of using pass-through entities. In these situations, or in this specific one, that was Leidos. Leidos has been a fantastic partner. Obviously, we might ultimately work with Leidos on plenty of other things, but as far as this specific contract goes, these services come from four separate companies: Amwell, Oracle Health, Philips. Oh, five actually. Solventum, the former 3M subsidiary, and Henry Schein. Before the end of July next year, DHA intends to create and execute contracts with all five of these companies. Will we ultimately see somewhat more revenue for additional services we might need to take on instead of third-party systems integrators and others? That's definitely a possibility.
All right. Among the few you listed, yours is the sole telehealth platform. The rest matter, sure, yet essentially each supplies separate components of the whole undertaking. All right, many thanks.
Of course, David. Of course.
Thanks for that, and I appreciate you fielding my question. I just want to confirm something about this DHA contract — does the yearly revenue shift at all from what the existing setup brings in? Or is the main upside simply that we now enjoy better visibility into the contract plus a longer term? I'm just attempting to get clarity on what's different here.
Clearly, there's a chance for additional services to be delivered straight by Amwell to the DHA. A variety of items are under discussion right now, and we'd anticipate a wider scope of services becoming possible.
For my next question, regarding what you said about solid renewals and an expanding pipeline — could you tell us whether that pipeline is growing thanks to customers you already have, or are you now seeing new logos, fresh customers arriving? What portion of these pipeline conversations involve some of the AI focus and the investment you're making in that area? I'm simply trying to get a handle on AI versus non-AI, plus existing versus new customers.
Hello, Jailendra. The answer is yes on every count. Essentially, a lot of the market participants today are looking for platforms. Vendor fatigue, the cost of engagement, matters I mentioned before. The market is certainly alive and kicking when it comes to switching platforms. They wish to switch platform also since they want, or at times are compelled, to add additional programs, because certain new programs are simply very effective. A number of them are dangerous and ineffective, and telling which is which is difficult. One thing is certain: handling it on your own is unbelievably taxing, extremely expensive, extremely complicated, extremely hard, and that is what we have been doing for a very long time, and that is what our platform handles. There's huge interest from new players in what we offer, but that interest is truly driven largely by the success we observe among our current customers. Regarding the DHA elephants—and there are quite a few others—they're basically delivering strong results. You can see that reflected in renewals. As for AI, it transforms everything; I can't really exaggerate how massive this upheaval is, affecting every area, and of course not only healthcare. To start, in a rather unglamorous fashion, we're deploying AI across the entire organization in everything we do. Improved outputs, improved processes, improved strategy powered by data, improvements everywhere. You saw the striking change in our cost structure, something that just couldn't have been done without AI. We've still got a long way to go. The reason we'll see a dramatic jump in effectiveness is simply that AI is now in the picture, and my guess is plenty of other companies are pursuing the same path. Whether it sets you apart is debatable, but from where we sit, not making the attempt carries existential risk. On a larger note, our infrastructure and product side reflects AI spending too — within our own offerings, across data analytics management, data science work, and so forth. Taking the widest view, what we really deliver is relief for customers: they no longer must be diligent about integrating and stitching together so many new programs. People rely on us for that work, and that’s exactly what our platform is built to handle—and we handle it very effectively. It matters enormously that we maintain a nationwide network of thousands of physicians available at all hours, with brief waits, deep experience, strong clinical quality, and exceptionally high NPS, all linked to and actively involved with this platform. If you want to realize a great deal of what both new and mature clinical programs are capable of achieving, having an actual clinician take part in the process is truly essential. Given that we recently secured renewals across very large audiences, and given that our marketing toward individuals — members, patients, beneficiaries, employees, whatever label you prefer — has gotten far stronger, we can boost engagement per person dramatically. That produces measurable outcomes we are able to demonstrate, and the capacity to transition and keep watch is something our customers consider rather elementary and essential. It can generate — and indeed already is generating, as some of today's figures showed — greater utilization among the customers we already have. It's difficult to overstate how large the same-store growth opportunity is. That expansion and that achievement have certainly had, already have had, and will keep having a substantial effect on our capacity to sell; we sell what works, and what works applies to the customers we already serve. Our focus is on maximizing value for them, and in a period of tremendous hardship and tremendous need, that represents the finest sales and marketing instrument for attracting new ones; we aren't seen as an unnecessary SaaS cost. Instead, we're seen as something that helps consolidate, save, simplify, and deliver results in a highly meaningful manner.
Excellent. That's great. Many thanks.
Yeah, appreciate it. So the set of opportunities seems to be moving toward those government initiatives you've mentioned. Could you share what you're observing among your health system clients? What's landing well with them right now? Which things are getting the most attention, and where might they be pulling back?
Absolutely, Craig. Basically, everyone is attempting to accomplish what I described, correct? Each one has a population they can reach that must be engaged so they adopt more care delivered through technology and driven by AI, which enhances results and betters them. And when that fails, you repair it; that applies universally. The government, clearly, represents an enormous framework—or an enormous vessel—holding many individuals who are strongly affected by the worth we're able to generate, and you can observe the traction there; the traction is nearly identical among commercial payers. We observe this quite plainly. What they care about aligns. Their customers—employers, particularly those self-insuring—are insisting on that kind of framework, that kind of nimbleness and capacity to get better. The matter with health systems is distinct; previously we maintained an extremely broad portfolio spanning various domains. A number of those are increasingly taken over by the established EHR vendors—urgent care, as an illustration, telepsychiatry which we divested not long ago, and similar items. Although we do see—and we do possess a devoted customer base among health systems, and that relationship makes us proud, and we think providers will also hold a crucial part going forward in making AI-driven care possible—the monetary chance at present that actually shifts our needle sits largely within government and payer segments when it comes to priorities. We are definitely not writing off the health systems. By their nature, they're more modest, they operate with differing dynamics. The area we concentrate on now is far more sharply delineated than previously, which I view as quite favorable for everyone; we aren't pursuing activities we lack excellence in; we perform a single thing, and we believe we excel at it. That carries a quite obvious consequence for every participant. Our priorities were, as stated, what they were.
Understood. To build on that for Mark — say you manage to return to growth in the double digits, could you discuss the operating leverage built into the model right now? I realize a great deal of cost cutting has already happened and things have been tightened up. Under that double-digit revenue outlook, how do you picture OpEx when it comes to headcount, or just broadly, even if only at a high level?
Yes, Craig — by the time we reach the back half of this year, the bulk of our cost reduction work will be behind us. We should see our margin profile improve by roughly 1,000 — around 1,000 basis points — comparing where we stand now against our Q4 2027 run rate, once we deliver a meaningful lift on the subscription revenue line. The expense required to run that line, keep it expanding, and support it is far lower than what we previously carried, since services now make up a bigger share. Our expectation is that headcount stays roughly flat, with what I'd call mid-teens growth projections across the years, provided every prospect we view as having a strong likelihood of signing, from today through the close of next year, actually comes through.
Got it. Thank you.
Welcome.
Hello there. Evening to you. I appreciate you fielding my questions. My apologies if I'm covering ground you've already addressed — I joined the call somewhat behind. Based on what you said about the pipeline growing, is there anything shifting in terms of R&D or sales and marketing priorities on your end, or any reinvestment, when we look ahead over the coming 6 to 12 months? Also, I had a quick follow-up: are you evaluating any chances to further streamline or rationalize non-core assets you hold? Thanks.
Hey, Stan. Those two parts of what you asked actually fit together really well. We're extremely focused; there's a single platform doing what I described earlier during this call, which means we're divesting things that aren't core, and we'll pour our efforts back into what I described earlier during this call. Our R&D group operates far more efficiently these days. It's considerably leaner than it once was, yet it delivers more in a lot of respects, largely thanks to that strategic focus, and also thanks to the layering, the reorganization, various processes, and heavy reliance on AI along with other tools; that's precisely what will keep letting us operate very effectively. Certain contracts we're evaluating, or certain opportunities, might call for some investment, yet those investments will be accretive and won't alter where we stand when we discuss growth and profitability. We're extremely disciplined these days, far more so than previously, about pursuing only opportunities that don't force us to lose focus and don't force us into custom development or anything whose profitability isn't clear. There's a single engine, and it performs one very specific function. It can be customized, but we aren't building any separate variant of it for separate customers. Everyone relies on the identical backbone, used the same way, and that lets us be far more impactful. In a lot of respects, I'd say part of the pipeline growth we're seeing, and part of why our story lands, comes down to it being genuinely trustworthy. Right now there are so many casualties, including among various programs — particularly new AI initiatives and such — that aren't necessarily working out, that trying them is unavoidable, But trying them on a platform you can trust, one that delivers a consistent member experience, that produces consistent reports in a consistent format, that needs just one integration, that cuts down the contracts and relationships you must oversee. On top of that, it powers a flywheel where one patient can receive multiple service types that strengthen one another and operate in harmony — that's why revenue per employee, the company's impact, its profitability, will, in our view, keep rising across the coming years.
Thanks for those details. Ido, it sounds as though you acknowledged there could be certain non-core assets that might get sold off. From a timing perspective, is there anything you can trim down and hint that something could be coming soon, or is this basically just a hypothetical idea that might or might not take place? Thank you.
Hypothetical isn't the right word for it; we've already shed a fair number of things. Our customers matter enormously to us, which makes them priority number one. No matter what steps we take, they'll be handled responsibly so that key market relationships stay intact and nobody ends up facing any kind of problem. That effort is underway right now. You ought to anticipate that we'll keep pulling back our focus. There could be some revenues attached. Or income, not revenues, my apologies. What matters most is how sharply the company concentrates. We intend to end up with a single platform, a single product, 1 category of service for every person we serve.
Excellent. Many thanks.
Thanks, operator, and I appreciate all of you being here. Enjoy your evening.
We appreciate everyone joining us for this call today. That brings the session to a close. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Well Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to American Well Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.